Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Cha

Showing results (301-310 of 317) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
European Urology|August 18, 2015
Genomic Characterization of Upper Tract Urothelial CarcinomaJohn P Sfakianos, Eugene K Cha, Gopa Iyer, et al.
BJU International|October 16, 2015
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-GuérinPaolo Gontero, Richard Sylvester, Francesca Pisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell TumorsAditya Bagrodia, Byron H Lee, William Lee, et al.
Nature Genetics|February 23, 2016
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancerHikmat A Al-Ahmadie, Gopa Iyer, Byron H Lee, et al.
Clinical Genitourinary Cancer|June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant ChemotherapyMin Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology|June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular PhenotypeNima Almassi, Karissa Whiting, Antoun Toubaji, et al.
European Urology|January 31, 2012
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinomaEugene K Cha, Shahrokh F Shariat, Matthias Kormaksson, et al.
European Urology|April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial CarcinomaCarissa E Chu, Ziyu Chen, Karissa Whiting, et al.
European Urology|July 22, 2014
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patientsPaolo Gontero, Richard Sylvester, Francesca Pisano, et al.
Pageof 32

Showing results (301-310 of 317) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
European Urology|August 18, 2015
Genomic Characterization of Upper Tract Urothelial CarcinomaJohn P Sfakianos, Eugene K Cha, Gopa Iyer, et al.
BJU International|October 16, 2015
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-GuérinPaolo Gontero, Richard Sylvester, Francesca Pisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell TumorsAditya Bagrodia, Byron H Lee, William Lee, et al.
Nature Genetics|February 23, 2016
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancerHikmat A Al-Ahmadie, Gopa Iyer, Byron H Lee, et al.
Clinical Genitourinary Cancer|June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant ChemotherapyMin Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology|June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular PhenotypeNima Almassi, Karissa Whiting, Antoun Toubaji, et al.
European Urology|January 31, 2012
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinomaEugene K Cha, Shahrokh F Shariat, Matthias Kormaksson, et al.
European Urology|April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial CarcinomaCarissa E Chu, Ziyu Chen, Karissa Whiting, et al.
European Urology|July 22, 2014
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patientsPaolo Gontero, Richard Sylvester, Francesca Pisano, et al.
Pageof 32